This educational video is for cancer patients and caregivers to learn more about comprehensive molecular profiling and how these advanced technologies can provide a blueprint of what makes up each patient’s unique cancer. With this personalised profile of results, the physician and patient can be confident and fully informed when creating a personalised cancer treatment plan specific for the patient.
The era of precision medicine has arrived, but what does that mean and how can tumour profiling help cancer patients? As the pioneer in comprehensive tumour profiling, Caris Life Sciences has developed a versatile approach that reveals the unique characteristics of a person’s cancer (DNA, RNA and Proteins) and can help patients, physicians and researchers...
Christie and her oncologist, Dr. Tim Dorius, share how her Caris Molecular Intelligence test provided a personalised approach to treat her lung cancer. Transcript: Christie: I have two wonderful children. I have a daughter who lives in Waverly and she has three kids. My son just lives half a mile down the road, and he...
• Sandy’s cancer, first diagnosed in 1992, recurred in 2002 in her liver, bone and lungs.
• Standard therapies were no longer working, so she tried tumour profiling, to identify personalised medicine.
• Anti-cancer drugs identified through molecular profiling, have managed her cancer and given her the time to experience her children’s graduations, marriages and birth of grandchildren.
• Melanie experienced cancer, recurring at different sites for seven years.
• Caris tumour profiling of her colorectal cancer revealed it had markers common to breast and kidney cancer.
• She’s doing well, after receiving targeted therapies, usually used to treat completely different types of cancer.
• Doug was given one year to live when first diagnosed with cancer
• He had molecular profiling of his cancer’s DNA, RNA and proteins performed with Caris
• Years later, he’s “doing well”, watching his grandchildren grow up.
Caris Centres of Excellence lead the development of scientific evidence for the molecular profiling of cancer tumours, to advance precision medicine.
• Diane was diagnosed with Stage 4 metastatic cancer of unknown origin, which had spread to the lung and liver.
• Caris Molecular Intelligence identified the PDL1 gene as a potential target for immunotherapy.
• After 12 weeks of immunotherapy, the two tumours in Diane’s lungs had disappeared. The liver tumour had halved in size.
• Molecular profiling helps doctors understand why tissues change to be cancerous, and which genetic mutations are driving cancer growth.
• Anti-cancer drugs can then be matched to genetic mutations in the tumour.
• Breakthroughs in molecular profiling of tumours are enhancing cancer treatment.
• Tumour profiling provides unique information to enable personalised cancer treatment.
• Caris Life Sciences uses a multi-technology platform to generate the most comprehensive tumour profile available.
• Fast reliable results identify new treatment options for patients who have not responded to the standard of care therapy.